Managers / Q1 2025 · view latest →
Forefront Analytics, LLC
CIK 0001696802 · ONE TOWER BRIDGE, 100 FRONT STREET, SUITE 1111, WEST CONSHOHOCKEN, PA, 19428 · 6103413900
Summary
Forefront Analytics, LLC reported $87M in U.S.-listed holdings across 72 positions for Q1 2025.
The portfolio is heavily concentrated: Nushares Etf Tr alone accounts for 25.9% of reported value.
Compared with Q4 2024, the fund opened 2 new positions and exited 21.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- ETP · 93.2% · $81M
- Common Stock · 5.9% · $5M
- Other · 0.6% · $481,513
- ADR · 0.4% · $325,836
Quarter-over-Quarter Changes full breakdown →
vs Q4 2024 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| 4I1PHILIP MORRIS INTL INC | NEW | +1.4K | 1.4K | +$222,000 | $222,000 |
| LEGNLEGEND BIOTECH CORP | NEW | +6.4K | 6.4K | +$218,564 | $218,564 |
| GONGERON CORP | ADDED | +44.0K | 63.0K | +$32,610 | $99,951 |
| ZURA BIO LTD | ADDED | +54.6K | 108.3K | +$5,464 | $139,801 |
| VANGUARD CHARLOTTE FDS | SOLD OUT | −318.1K | 0 | −$16M | $0 |
| ISHARES TR | SOLD OUT | −147.4K | 0 | −$13M | $0 |
| AOKISHARES TR | SOLD OUT | −347.3K | 0 | −$13M | $0 |
| SPDR SER TR | SOLD OUT | −217.6K | 0 | −$8M | $0 |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q1 2025
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | NUSHARES ETF TR | NUVEEN ESG LRGVL | 25.85% | $22M | 555.0K |
| 2 | ISHARES TR | MSCI USA MMENTM · CORE HIGH DV ETF · MSCI USA MIN VOL · CORE S&P500 ETF · MSCI INDIA ETF · GLB INFRASTR ETF · TIPS BD ETF · 3 7 YR TREAS BD · 7-10 YR TRSY BD | 25.29% | $22M | 155.9K |
| 3 | SPDR SER TR | SPDR S&P 500 ETF | 10.73% | $9M | 203.9K |
| 4 | VANGUARD INTL EQUITY INDEX F | FTSE EMR MKT ETF | 8.17% | $7M | 156.9K |
| 5 | VANGUARD TAX-MANAGED FDS | VAN FTSE DEV MKT | 6.39% | $6M | 109.3K |
| 6 | DBX ETF TR | XTRACK MSCI EAFE | 5.34% | $5M | 107.2K |
| 7 | VTVVANGUARD INDEX FDS | VALUE ETF · SMALL CP ETF | 3.93% | $3M | 18.6K |
| 8 | ISHARES INC | CUR HD MSCI EM | 2.07% | $2M | 64.0K |
| 9 | NVDANVIDIA CORPORATIONhistory → | COM | 1.85% | $2M | 14.9K |
| 10 | SPDR S&P 500 ETF TR | TR UNIT | 1.76% | $2M | 2.7K |
| 11 | WISDOMTREE TR | US SMALLCAP FUND | 1.46% | $1M | 26.0K |
| 12 | JPMJPMORGAN CHASE & CO. | COM | 0.93% | $810,000 | 3.3K |
| 13 | PROSHARES TR | PSHS ULT S&P 500 · PSHS ULTRUSS2000 | 0.69% | $598,369 | 11.9K |
| 14 | DEDEERE & CO | COM | 0.61% | $527,000 | 1.1K |
| 15 | FIRST TR EXCHANGE-TRADED FD | NO AMER ENERGY | 0.57% | $498,000 | 13.3K |
| 16 | PIMCO ETF TR | 15+ YR US TIPS | 0.47% | $405,000 | 7.4K |
| 17 | UNHUNITEDHEALTH GROUP INC | COM | 0.45% | $392,813 | 750 |
| 18 | EWEDWARDS LIFESCIENCES CORP | COM | 0.38% | $333,915 | 4.6K |
| 19 | MEDTRONIC PLC | SHS | 0.29% | $250,946 | 2.8K |
| 20 | TMOTHERMO FISHER SCIENTIFIC INC | COM | 0.26% | $225,596 | 453 |
| 21 | 4I1PHILIP MORRIS INTL INC | COM | 0.26% | $222,000 | 1.4K |
| 22 | BARCLAYS BANK PLC | DJUBS CMDT ETN36 | 0.25% | $216,000 | 6.1K |
| 23 | LEGNLEGEND BIOTECH CORP | SPONSORED ADS | 0.24% | $204,564 | 6.0K |
| 24 | PFEPFIZER INC | COM | 0.23% | $203,783 | 8.0K |
| 25 | INVESCO EXCH TRADED FD TR II | SR LN ETF | 0.23% | $203,000 | 9.8K |
| 26 | INCYINCYTE CORP | COM | 0.22% | $189,643 | 3.1K |
| 27 | ZURA BIO LTD | CLASS A ORD SHS | 0.15% | $129,801 | 100.6K |
| 28 | MREOMEREO BIOPHARMA GROUP PLC | SPON ADS | 0.11% | $99,272 | 44.1K |
| 29 | GONGERON CORP | COM | 0.11% | $92,951 | 58.5K |
| 30 | COGTCOGENT BIOSCIENCES INC | COM | 0.09% | $77,487 | 12.9K |
| 31 | IMMATICS N.V | SHS | 0.08% | $66,766 | 14.8K |
| 32 | 2662247DITEOS THERAPEUTICS INC | COM | 0.07% | $61,366 | 10.3K |
| 33 | CTMXCYTOMX THERAPEUTICS INC | COM | 0.07% | $59,141 | 93.0K |
| 34 | ANNXANNEXON INC | COM | 0.06% | $51,326 | 26.6K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $110M | 39 | May 13, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $113M | 47 | Feb 17, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $104M | 46 | Nov 21, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $90M | 47 | Aug 14, 2025 | RESTATEMENT | changes · EDGAR ↗ |
| Q1 2025 | $87M | 72 | May 13, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $215M | 113 | Feb 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $212M | 114 | Nov 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $209M | 114 | Aug 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $206M | 113 | May 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $203M | 112 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $176M | 67 | Nov 8, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $175M | 115 | Aug 11, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $194M | 138 | May 12, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $188M | 130 | Feb 13, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $188M | 115 | Nov 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $206M | 114 | Aug 10, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $269M | 119 | May 9, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $299M | 109 | Feb 11, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $274M | 118 | Nov 15, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $252M | 113 | Aug 10, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $235M | 114 | May 13, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $230M | 109 | Feb 12, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $214M | 98 | Nov 12, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | Under review | 92 | Aug 10, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | Under review | 179 | May 11, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $257M | 77 | Feb 5, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $243M | 76 | Nov 5, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $235M | 69 | Aug 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $157M | 69 | May 13, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q4 2018 | $181M | 73 | Feb 12, 2019 | 13F-HR | changes · EDGAR ↗ |
Other Included Managers
This filing reports holdings on behalf of 1 additional manager.
- GKFO LLC
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.